The Misconception That Won’t Quit: GLP-1s Are Just For Weight Loss
I cannot tell you how many conversations I’ve had where someone mentions their cousin’s Ozempic prescription and immediately assumes it’s purely cosmetic. That assumption is understandable, given how the medications exploded into popular culture as weight-loss drugs. But I’ve spent the last seventy-two hours reading through recent clinical data, and I need to correct something fundamental: we are watching the early stages of a pharmaceutical story that extends far beyond the scale.
The problem is that weight loss was never the primary pharmacological purpose of these compounds. GLP-1 receptor agonists were developed decades ago to manage blood glucose in diabetic patients. What happened over the past five years was that we discovered the receptor itself sits on neural tissue involved in appetite regulation, and separately, that it influences cardiovascular and metabolic pathways with almost surprising breadth. It’s like discovering that a tool you’ve been using for one job actually works remarkably well for three others, and we’re only now cataloging what those additional jobs actually are.
The Cardiovascular Pivot: When Non-Diabetic Hearts Started Responding
Here’s where my 3am research session got genuinely riveting. The SELECT trial, which followed more than seventeen thousand non-diabetic people with obesity and established cardiovascular disease, demonstrated that semaglutide reduced major cardiovascular events—heart attacks, strokes, cardiovascular death—by approximately 20 percent compared to placebo. You can read the SELECT Trial Results – New England Journal of Medicine yourself if you want the technical breakdown. The trial ran through 2025, and what matters is this: we now have evidence that these medications work on non-diabetic cardiovascular disease through mechanisms that have nothing to do with blood sugar management.
The cardiovascular benefit appears to operate through weight reduction, yes, but also through direct effects on inflammation, endothelial function, and probably pathways we haven’t fully characterized yet. This changes how we think about risk stratification. A cardiologist is no longer looking at these drugs as weight-loss adjuncts. They’re looking at them as potential primary prevention tools for a specific subset of patients. The old assumption was that cardiovascular benefit required diabetes first. The data says otherwise.
The Addiction and Dopamine Frontier: A Controversy That Reveals What We Don’t Know
This is the piece that kept me reading until morning light started filtering through my window. A 2025 study published in the New England Journal of Medicine found that semaglutide reduced alcohol cravings and use disorder symptoms in approximately 30 percent of trial participants. I want to be clear immediately: this was not a primary efficacy endpoint in a massive trial. This was an observation, a signal in the data that sparked serious questions. And those questions have ignited a real debate within neuropharmacology and addiction medicine.
The hypothesis centers on dopamine pathway modulation. GLP-1 receptors exist in brain regions associated with reward processing, and some researchers propose that the drug’s effects on these regions could reduce the motivational pull of addictive substances. But here’s what makes this both exciting and complicated: we don’t actually know if this is causation or correlation. We don’t know if weight loss itself reduces addiction cravings through separate psychological mechanisms. We don’t know how long the effect lasts. What we know is that the signal is real enough to warrant follow-up investigation. The media conflated preliminary observation with confirmation. The addiction medicine community has been appropriately cautious.
Cancer Risk, Sleep Apnea, and the Branching Pathway Forward
A meta-analysis published in Nature Medicine in 2025 pulled data from approximately eighty-five thousand patients and found that GLP-1 receptor agonists were associated with a 40 to 70 percent reduced risk across ten obesity-related cancers. The range varies by cancer type, which matters because it suggests the mechanisms aren’t uniform. Colorectal cancer risk reduction looks different from endometrial cancer risk reduction. This granularity is exactly what rigorous science requires, and it also suggests we’re only beginning to understand the full pharmacology at work.
Then there’s the obstructive sleep apnea approval. In June 2024, the FDA approved tirzepatide—Eli Lilly’s GLP-1 competitor—specifically for treating sleep apnea in adults with obesity. You can review the FDA Approval of Tirzepatide for Sleep Apnea if you want the regulatory details. This matters because sleep apnea had no pharmacological treatment before this moment. The options were always weight loss, CPAP machines, or surgery. Now we have a drug specifically approved for this indication. That’s a genuine category expansion.
A lot of people assume these medications do one thing very well. The data increasingly shows they do multiple things reasonably well, and the cascade of effects seems to come from weight loss plus direct receptor-mediated mechanisms. We’re not talking about a magic bullet. We’re talking about a compound with pleiotropic effects, meaning multiple downstream consequences from a single mechanism.
The Market Reality and What It Means for Medicine’s Future
Novo Nordisk reported that Ozempic and Wegovy sales exceeded twenty-five billion dollars globally in 2024. That makes semaglutide one of the ten best-selling pharmaceutical products in history, across all time periods. That number is staggering, and it reflects both genuine unmet medical need and the reality that we’ve been underestimating how much of the population could benefit from these medications beyond simple weight management.
What concerns me, and what I think is worth saying plainly, is the assumption that these drugs solve obesity. They don’t. They’re tools that help manage it. Discontinuation usually leads to weight regain. They carry side effects that some patients cannot tolerate. They work better for some people than others, for reasons we don’t fully understand. But what the emerging data from 2025 tells us is that for the people they do help, the benefits may reach into domains we didn’t initially recognize: cardiovascular protection, addiction reduction potential, cancer risk mitigation, and sleep disorder management.
We are in the early-to-middle chapters of understanding these compounds. The assumption I hope we correct collectively is that we’ve figured them out. We haven’t. We’ve just discovered that the story is far more interesting than a single-indication narrative. If you’ve been reading about GLP-1s primarily in the context of weight loss, follow the emerging literature on cardiovascular outcomes and the mechanistic investigations into how these receptors might be influencing disease pathways we barely knew existed. The science is moving fast, and the implications are genuinely profound.